Quotient Sciences Chief Scientific Officer Dr. Andrew Lewis discusses how machine learning can guide formulation optimization using emerging clinical data, helping sponsors identify promising formulations sooner while reducing development time, API use and unnecessary formulation iterations
Connecting Formulation, Manufacturing and Clinical Data to Make Faster Decisions
Quotient Sciences’ integrated approach brings formulation development, drug product manufacturing and clinical testing together within a single development model. This can reduce the traditional hand-offs between different providers while allowing formulation scientists to respond rapidly to emerging clinical data.
Read the full article on biopharmaboardroom.com website.